AnaptysBio, Inc. (ANAB)

AnaptysBio's stock experienced a significant increase of 262.87% in 2025 and delivered a 214% return over the past year. Key events include an ongoing legal dispute with GSK/Tesaro, an amended $100 million stock repurchase plan, and the discontinuation of the ulcerative colitis study of Rosnilimab after Phase 2 trial results. The company intends to separate its biopharma operations from its royalty assets by year-end 2026 and anticipates a $75 million milestone payment from GSK in Q4 2025. There have been insider sales in December 2025 and January 2026.

AnaptysBio's direct product and service demand is not subject to typical seasonality. Demand for its pipeline products is driven by clinical trial progress, regulatory approvals, and the prevalence of the diseases they aim to treat. Revenue is influenced by collaboration agreements and milestone payments related to out-licensed products.

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases. Its pipeline includes Rosnilimab, ANB032, ANB033, and ANB101. The company has also out-licensed therapeutic antibodies like Jemperli to GSK and Imsidolimab to Vanda Pharmaceuticals.

AnaptysBio, Inc. is headquartered in San Diego, California, United States. Its operational footprint is primarily in the U.S., while its out-licensed products have a worldwide sales presence.

AnaptysBio maintains a generally positive brand reputation with a consensus rating of "Moderate Buy" and an average rating score of 2.83. Several firms have reiterated "Buy" or "Outperform" recommendations, and UBS initiated coverage with a "Buy" rating in January 2026. The company's reputation has been impacted by the ongoing legal dispute with GSK and Tesaro. AnaptysBio's financial health is rated "GOOD" by InvestingPro analysis.

Approximately 95.70% of AnaptysBio's outstanding shares are held by institutional investors, including EcoR1 Capital, LLC, Point72 Asset Management, L.P., and BlackRock, Inc. Individual insiders, such as Ecor1 Capital LLC and Oleg Nodelman, also hold a notable percentage of the company's stock.